Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$51.72
-1.0%		$53.49
$44.12
▼
$78.48
$5.00B1.761.42 million shs855,572 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$11.74
-1.6%		$12.45
$7.95
▼
$28.25
$1.65B1.823.22 million shs2.71 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-1.03%-7.30%-4.20%+3.86%-0.17%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-1.59%-7.85%-2.89%-3.06%+3.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$51.72
-1.0%		$53.49
$44.12
▼
$78.48
$5.00B1.761.42 million shs855,572 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$11.74
-1.6%		$12.45
$7.95
▼
$28.25
$1.65B1.823.22 million shs2.71 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-1.03%-7.30%-4.20%+3.86%-0.17%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-1.59%-7.85%-2.89%-3.06%+3.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.61
Moderate Buy$68.0631.58% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.35
Hold$20.9878.69% Upside

Current Analyst Ratings Breakdown

Latest NTLA and CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$30.00
9/9/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$12.00 ➝ $13.00
9/9/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$82.00
8/25/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/25/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/25/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
8/25/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$30.00
8/7/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Outperform$24.00
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,424.73N/AN/A$20.17 per share2.56
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$67.67M24.31N/AN/A$5.80 per share2.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.76N/AN/AN/A-3,368.72%-24.39%-18.25%11/9/2026 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$412.69M-$3.36N/AN/AN/A-672.16%-57.79%-47.29%11/5/2026 (Estimated)

Latest NTLA and CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$0.7993-$0.80-$0.0007-$0.80$12.98 million$7.66 million
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.19-$0.94+$0.25-$0.94$7.45 million$10.18 million
6/30/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$0.94N/A-$0.94N/A$10.18 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.34
17.85
17.85
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
6.65
6.65

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39396.69 million91.67 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
377140.13 million135.22 millionOptionable

Recent News About These Companies

Citizens Jmp Reaffirms Market Outperform Rating for Intellia Therapeutics (NASDAQ:NTLA)
September 11 at 2:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016042
Wedbush Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $13.00
September 11 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015839
HC Wainwright Reiterates "Buy" Rating for Intellia Therapeutics (NASDAQ:NTLA)
September 11 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015832
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)
September 10 at 1:09 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/COLL/pressreleases/4532330/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla/
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
September 9 at 11:05 AM  |  zacks.comhttps://www.zacks.com/stock/news/2987043/fda-accepts-gives-priority-review-to-intellia-s-bla-for-hae-drug?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2987043
Intellia Therapeutics' (NTLA) Market Outperform Rating Reiterated at Citizens Jmp
September 9 at 9:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-intellia-therapeutics-ntla-market-outperform-rating-reiterated-at-citizens-jmp-2026-09-09/
Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $13.00 at Wedbush
September 9 at 8:29 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-intellia-therapeutics-nasdaq-ntla-price-target-raised-to-1300-at-wedbush-2026-09-09/
Intellia Therapeutics' (NTLA) "Buy" Rating Reaffirmed at HC Wainwright
September 9 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-intellia-therapeutics-ntla-buy-rating-reaffirmed-at-hc-wainwright-2026-09-09/
Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating
September 8, 2026  |  marketscreener.comM
Intellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027
September 8, 2026  |  rttnews.comhttps://www.rttnews.com/3689223/intellia-s-lonvo-z-bla-gets-fda-priority-review-for-hereditary-angioedema-pdufa-set-for-march-2027.aspx
Cathie Wood’s biotech bet Intellia secured an FDA priority review for rare genetic disorder therapy – retail sees upside in NTLA’s platform
September 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/cathie-wood-s-biotech-bet-intellia-secured-an-fda-priority-review-for-rare-genetic-disorder-therapy-retail-sees-upside-in-ntla-s-platform/ar-AA2bOHP5
3 Promising Genomics Stocks in the Spotlight in 2026
September 8, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986615/3-promising-genomics-stocks-in-the-spotlight-in-2026?cid=cs-stocknewsapi-ft-genomics_&_synthetic_biology-2986615
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/intellia-therapeutics-shares-rise-fda-124838191.html
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4640746-intellia-stock-rises-fda-priority-review
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357599/0/en/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-lonvoguran-ziclumeran-lonvo-z-for-hereditary-angioedema-hae.html
Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-invests-149-million-in-intellia-therapeutics-inc-ntla-2026-09-08/
Legal & General Group Plc Invests $1.93 Million in Intellia Therapeutics, Inc. $NTLA
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-193-million-in-intellia-therapeutics-inc-ntla-2026-09-07/
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
September 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/intellia-therapeutics-ntla-secures-400-161327947.html
Intellia Therapeutics Enters $400 Million OrbiMed Term Loan Facility
September 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/intellia-therapeutics-enters-400-million-131848790.html
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356788/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Intellia Secures Up To $400 Mln Non-Dilutive Debt Facility From OrbiMed
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688641/intellia-secures-up-to-400-mln-non-dilutive-debt-facility-from-orbimed.aspx

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$51.72 -0.54 (-1.03%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$51.76 +0.05 (+0.09%)
As of 09/11/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$11.74 -0.19 (-1.59%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$11.78 +0.04 (+0.38%)
As of 09/11/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas